At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 34 enrolled
Drug / intervention
RTH258drug
Likely dose
RTH258 6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Arm, Multicenter, Phase IIIb Study in Patients With Neovascular Age-Related Macular Degeneration to Evaluate the Safety of Brolucizumab 6 mg in Prefilled Syringe
In Brief
A Phase 3 clinical trial evaluating RTH258 for Neovascular Age Related Macular Degeneration. Completed, enrolled 34 participants across 3 sites.
Detailed Summary
This was a multicenter, open label study that is designed to evaluate the safety of brolucizumab 6 mg in a prefilled syringe in subjects with neovascular age related macular degeneration and to support collection of observations of the prefilled syringe use for intravitreal injection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartMay 2019
Primary CompletionJul 2019
TodayJul 2026
First PostedApr 29, 2019
Enrollment StartMay 23, 2019
Primary CompletionJul 2, 2019
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 7.2 years ago
Interventions
RTH258drug
6 mg in prefilled syringe